

Independent Medical Education Request for Proposals

Improving Shared Decision Making in Hemophilia: Visiting Professorship Program- 2026, Semester 2

Summary of Opportunity

Overview

Pfizer and the Hemostasis & Thrombosis Research Society (HTRS) are offering a new Independent Medical Education grant opportunity supporting Visiting Professorships for organizations with identified needs for hemophilia-focused education.

Clinicians, physician-scientists, multidisciplinary care teams and patient advocacy group members at recipient organizations will host and coordinate a medical education program led by a distinguished Visiting Professor with expertise matched to specific unmet educational needs surrounding shared decision making (SDM) and emerging therapeutic options in hemophilia.^{1,2}

About Hemostasis & Thrombosis Research Society

The Hemostasis and Thrombosis Research Society, Inc. (HTRS) is the leading North American professional society dedicated to research, mentoring, workforce development, and continuing medical education for physicians, investigators, and all health care professionals interested in advancing care for people with hemostatic and thrombotic disorders.

About Pfizer

Pfizer supports the global healthcare community's independent education initiatives to improve patient outcomes in areas of unmet medical need that are aligned with medical and/or scientific strategies.

Eligibility

Geographic Scope

United States

Applicant Eligibility Criteria

- The following may apply: professional medical, nursing, allied health, dental, or pharmacy schools; universities and academic healthcare institutions (both large and small); patient advocacy groups, nonprofit professional organizations or medical societies.
- Only organizations are eligible to receive grants (individuals or independent groups of physicians not affiliated with a hospital, academic institution, or professional society are not eligible).

- If the project involves multiple departments within a single institution or is between different institutions, organizations, or associations, each institution, including the requesting organization, must play a defined and relevant role in the project.
- The applicant organization must identify an individual to serve as the Project or Program Lead (e.g., the grant coordinator from the applicant organization).
- The Project or Program Lead must be an employee or contractor of the requesting organization.
- For projects offering continuing education credit, the requesting organization must supply proof of accreditation.

Requirements

Primary Area of Interest

Hemophilia

Specific Area of Interest for this RFP

The intent of this Request for Proposals (RFP) is to invite healthcare institutions and/or patient advocacy groups with identified needs for hemophilia-focused education to submit applications to host **up to a 2-days** medical education program at their organization. The program will be led by **one or two Visiting Professor(s)**, identified by HTRS, with expertise matched to the organization's unmet educational needs surrounding SDM and emerging therapeutic options in hemophilia care.^{1,2}

Organizations interested in applying for a Visiting Professorship must complete the required online application form, including:

- A description of the Organization's medical gaps, unmet needs, challenges, and questions surrounding SDM and emerging therapeutic options for hemophilia care, for which a Visiting Professorship program could provide significant educational impact.
- The proposed agenda for a Visiting Professorship Program up to two-days in length
- Expected or desired outcomes, including an outline of 6-month outcome metrics describing enduring changes or improvements in patient care and physician education/knowledge made as a result of the Visiting Professorship Program.
- Proposed Budget of Logistics Expenses.
- Proof of Accreditation (if applicable).

Target Audience

Academic clinicians, physician-scientists, multidisciplinary care teams (MDTs) and patient advocacy groups.

Expected Approximate Monetary Range of Grant Applications

- Individual grant amounts will be up to **\$6,000 USD** to cover local costs (e.g., meeting room rental, AV support, local onsite management, onsite logistics, or planning and staffing needs).
- Please note: HTRS will select one Visiting Professor based on the recipient's approved program and knowledge gaps. Travel expenses and honoraria for the Visiting Professor will be covered separately and should not be a part of your grant application budget.
- Approximately **nine (9) sites** will be supported by this educational program.

Key Dates

- **RFP release date: June 25, 2026**
- Applications will be accepted on or before 5:00 PM ET on **September 17, 2026**, and will be reviewed per the timeline below:

Proposal Application Opening Period*	Deadline for Applications	Decision Notification Date	Program Start Date must be after
From September 3 to September 17	September 17, 2026 at 5:00 PM ET	October 30, 2026	January 1, 2027

***Due to Pfizer's transition to a new grant management system in July and August, submissions to the system will only be possible between September 3 and September 17, 2026.**

IMPORTANT: Applications submitted after 5:00 PM ET on September 17, 2026, will not be reviewed.

Components of a Completed Proposal

- Completed Application Form ([Download Here](#))
- Project Plan/Proposal or Meeting Agenda
- Letter of Support from the Organization
- Proposed Budget of Logistic Expenses
- Proof of Accreditation (if applicable)

How to Submit:

IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Click [here](#) to navigate to this Competitive Grant Program's unique **Program Application Form**.
- First-time users should create a Requester Portal account by clicking **Not a member?**

OR

- Navigate to: <https://pfizermarcie.my.site.com/pfzrequester> and sign in.
- In the upper navigation bar, click **Grant Programs** to see all available programs.
- Select **Medical Education**
- Click **Apply** on the 2026 RD US HTRS Hemophilia Visiting Professorship S2 IME to open the Program Application Form.

Requirements for submission:

- Complete all required sections of the online application
- **IMPORTANT: Upload proposal (see Appendix) in the Proposal/Protocol field.**
- For more information on navigating Pfizer's new grant management system (MARCIE), please refer to this helpful [User Guide](#).

Questions

- If you have questions regarding this RFP, please direct them in writing to Talita Honorato-Rzeszewicz at Pfizer (talita.honorato-rzeszewicz@pfizer.com) or Danielle Horwitz at HTRS (dhorwitz@htrs.org), with the subject line “Visiting Professorship RFP”.

Review and Approval Process

- Applications will be considered by an Expert Review Panel (ERP) empowered by Pfizer and HTRS to make final grant decisions. The Review Panel comprises professionals from the medical community identified by HTRS. Pfizer will also have a Medical colleague on the Review Panel.

Mechanism by which Applicants will be Notified

- All applicants will be notified via email on or before October 30, 2026.
- Applicants may be asked for additional clarification during the review period.

Grant Agreements

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Recipients are encouraged to share the core terms of the agreement with their legal counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the recipient organization.

References

1. Valentino, L. et al. Personalising haemophilia management with shared decision making. J Haem Pract 8(1), 2021.
2. Thornburg C., Coffin D. How clinicians and persons with hemophilia may approach shared decisionmaking. Exp. Rev. Hem. Vol 17 (6), 2024